Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells.
- Author:
Yu Ri KIM
1
;
Ki Seong EOM
Author Information
- Publication Type:Original Article
- Keywords: CXCR4; VLA-4; Mantle cell lymphoma; Microenvironment; Drug resistance
- MeSH: Antibodies, Bispecific; Antibodies, Blocking; Bone Marrow; Cell Line; Drug Resistance; Drug Therapy*; Integrin alpha4beta1*; Lymphoid Tissue; Lymphoma; Lymphoma, Mantle-Cell*; NF-kappa B; Phosphorylation; Prognosis; Stromal Cells
- From:Immune Network 2014;14(6):296-306
- CountryRepublic of Korea
- Language:English
- Abstract: There is growing evidence that crosstalk between mantle cell lymphoma (MCL) cells and stromal microenvironments, such as bone marrow and secondary lymphoid tissues, promotes tumor progression by enhancing survival and growth as well as drug resistance of MCL cells. Recent advances in the understanding of lymphoma microenvironment have led to the identification of crucial factors involved in the crosstalk and subsequent generation of their targeted agents. In the present study, we evaluated the combinatory effect of blocking antibodies (Ab) targeting CXCR4 and VLA-4, both of which were known to play significant roles in the induction of environment-mediated drug resistance (EMDR) in MCL cell line, Jeko-1. Simultaneous treatment with anti-CXCR4 and anti-VLA-4 Ab not only reduced the migration of Jeko-1 cells into the protective stromal cells, but also enhanced sensitivity of Jeko-1 to a chemotherapeutic agent to a greater degree than with either Ab alone. These combinatorial effects were associated with decreased phosphorylation of ERK1/2, AKT and NF-kappaB. Importantly, drug resistance could not be overcome once the adhesion of Jeko-1 to the stromal occurred despite the combined use of Abs, suggesting that the efforts to mitigate migration of MCLs should be attempted as much as possible. Our results provide a basis for a future development of therapeutic strategies targeting both CXCR4 and VLA-4, such as Ab combinations or bispecific antibodies, to improve treatment outcomes of MCL with grave prognosis.
